

French Guiana

Region of the Americas



I. Epidemiological profile


Population (UN)	2016	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	25,000	9	Plasmodium species: <i>P. falciparum</i> (24%), <i>P. vivax</i> (76%)
Low transmission (0-1 cases per 1000 population)	124,000	46	Major anopheles species: <i>An. darlingi</i>
Malaria-free (0 cases)	120,000	45	Reported confirmed cases (health facility): 131 Estimated cases: 160 [≤ 100-300]
Total	268,100		Confirmed cases at community level: - Reported deaths: 0 Estimated deaths: 0

II. Intervention policies and strategies


Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	No	2012	First-line treatment of unconfirmed malaria	-	-					
	ITNs/ LLINs distributed to all age groups	Yes	2005	First-line treatment of <i>P. falciparum</i>	AL	-					
IRS	IRS is recommended	Yes	-	Treatment failure of <i>P. falciparum</i>	AQ+PG	-					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	AS	-					
Larval control	Use of larval control recommended	Yes	-	Treatment of <i>P. vivax</i>	CQ+PQ(14d)	-					
IPT	IPT used to prevent malaria during pregnancy	N/A	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.50 mg/Kg (14 days)					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	-	Type of RDT used		P.f + all species (Combo)					
	Malaria diagnosis is free of charge in the public sector	Yes	-								
Treatment	ACT is free of charge for all ages in public sector	Yes	-	Therapeutic efficacy tests (clinical and parasitological failure, %)							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-	Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	-								
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	-								
	G6PD test is a requirement before treatment with primaquine	Yes	-								
	Directly observed treatment with primaquine is undertaken	No	-								
	System for monitoring adverse reactions to antimalarials exists	Yes	-								
Surveillance	ACD for case investigation (reactive)	No	-	Insecticide resistance tests (mosquito mortality, %)							
	ACD of febrile cases at community level (pro-active)	No	-	Insecticide class	Years	Min	Mean	Max	No. of sites	Species	
	Mass screening is undertaken	No	-								
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	Yes	-								
	Foci and case investigation undertaken	-	-								
Case reporting from private sector is mandatory	Yes	-									

III. Financing

Sources of financing




Government expenditure by intervention in 2016




IV. Coverage

Coverage of ITN and IRS




Cases tested and treated in public sector




V. Impact


Cases treated



Test positivity



Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths

